IFN-γ-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-γ

Journal of Immunology

Volumn 166, Issue 4, 2001, Pages 2276-2282

  Beatty, G L ^a   Paterson, Y ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR GROWTH; TUMOR REJECTION;

EID: 0035865188     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.4.2276     Document Type: Article

References (60)

1. Protection against syngeneic lymphoma by a long-lived cytotoxic T-cell clone
2. Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes
3. + cells: Cytolytic T cells can mediate eradication of disseminated leukemia
4. + T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ
5. - lymphocytes
6. - T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity
7. A unique tumor antigen produced by a single amino acid substitution
8. Cloned helper T cell can kill B lymphoma cells in the presence of specific antigen: Ia restriction and cognate vs. noncognate interactions in cytolysis
9. Cloned protein antigen-specific, Ia-restricted T cells with both helper and cytolytic activities: Mechanisms of activation and killing
10. - T cell receptor-αβ phenotypes generated in CD8-depleted C57BL/6 mice
11. + cytotoxic T lymphocyte clones display a Th1 cytokine profile and use a Fas-independent pathway for specific tumor cell lysis
12. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells
13. + T cell responses in antitumor immunity
14. + T cells in the antitumor immune response
15. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins
16. Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies
17. Distinct role of antigen-specific T helper type (Th1) and Th2 cells in tumor eradication in vivo
18. - T cells: Tumor eradication does not require participation of cytotoxic T cells
19. Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro
20. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN-γ receptors
21. Differential γ-interferon response of human colon carcinoma cells: Inhibition of proliferation and modulation of immunogenicity as independent effects of γ-interferon on tumor cell growth
22. Tumor cell responses to IFN-γ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis
23. Antiangiogenic gene therapy
24. Cellular responses to interferon-γ
25. Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon-γ and bacterial lipopolysaccharide
26. Immunosuppression and transforming growth factor-β in glioblastoma: Preferential production of transforming growth factor-β2
27. Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: Identification of transforming growth factor-β as a suppressive factor
28. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein-10
29. Interferon-γ-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases
30. Mig, the monokine induced by interferon-γ promotes tumor necrosis in vivo
31. IFN-γ can promote tumor evasion of the immune system in vivo by downregulating cellular levels of an endogenous tumor antigen
32. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells
33. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with note on carcinogen structure
34. Intracellular murine IFN-γ mediates virus resistance, expression of oligoadenylate synthetase, and activation of STAT transcription factors
35. The tumor recall response of antitumor immunity primed by a live, recombinant Listeria monocytogenes vaccine is comprised of multiple effector mechanisms
36. Determination of lymphocyte division by flow cytometry
37. Isolation and characterization of type IV procollagen, laminin, and heparin sulfate proteoglycan from the EHS sarcoma
38. Methods in laboratory investigation: A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin and fibroblast growth factor
39. Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12
40. B cells inhibit induction of T cell-dependent tumor immunity
41. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
42. Help for cytotoxic-T-cell responses is mediated by CD40 signalling
43. + T-helper and a T-killer cell
44. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12
45. In vivo priming of two distinct antitumor effector populations: The role of MHC class I expression
46. Surface receptors delivering opposite signals regulate the function of human NK cells
47. Transfection of β2-microglobulin restores IFN-mediated protection from natural killer cell lysis in YAC-1 lymphoma variants
48. NK susceptibility varies inversely with target cell class I HLA antigen expression
49. + T cell help
50. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
51. The role of CXC chemokines as regulators of angiogenesis
52. Multiple roles of interferon-γ in the mediation of interleukin 12-induced tumor regression
53. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production
54. A highly immunogenic tumor transfected with a murine transforming growth factor type β1 cDNA escapes immune surveillance
55. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN-γ receptor expression by nonhematopoietic cells
56. Human tumor antigens: Implications for cancer vaccine development
57. Tumor angiogenesis: Past, present, and the near future
58. Expression of vascular permeability factor/vascular growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis
59. The possible role of angiogenesis in the metastatic potential of human melanoma: Clinicopathological aspects
60. Extent of vascularization as a prognostic indicator in thin (<0.76 mm) malignant melanoma